What hasn't been mentioned for a while is that Cyrcadia Health has a distribution partner already set up for Singapre and south Asia through their partner Advance Medical Systems since last September.
Cyrcadia Health’s Singapore business partner, Romesh Kaul, CEO of Advanced Medical Systems, Pte. Ltd. (AMS), has been leading breast diagnostic and therapeutic innovations in South Asia for over 20 years. His introductions to a team of socially concerned angel investors promoted the latest round of funding, through CIS Agriferts, Pte Ltd and RB Investments Pte, Ltd . “Singapore adoption of advanced healthcare systems as a regional leader is well known,” said Kaul. “As the location of AMS’s headquarters, it shall serve Cyrcadia Health well and provide the basis for approaching the area’s medical institutions for clinical validations. AMS will work with leading providers for early adoption of Cyrcadia wearable technology throughout the region.”
Founded in 1988, Advanced Medical Systems Pte, Ltd, AMS is an established medical devices organization offering innovative. multi-disciplinary solutions for centers of excellence across the Asia Pacific region in Radiology, Neurosciences, Orthopedics & Oncology. AMS is the only organization of its kind to offer a complete range of services required for turnkey facility planning, technology implementation, training, management and finance. Headquartered in the Republic of Singapore, AMS directly serves the Asia/Pacific healthcare markets with operating bases and highly trained personnel in Australia, India, Malaysia and Singapore for advanced imaging and minimally invasive therapy systems and services. For more information visit Advanced Medical Systems at www.amssg.com or via Facebook at www.facebook.com/amssg Here's a link to Advanced Medical Systems website: http://www.amssg.com/AMS/Advanced_Medical_Systems.html
Cyrcadia Health is featured on the Advanced Medical Systems Facebook page. They are gearing up. https://www.facebook.com/amssg
Singapore will be the launch site for the initial sales of the iTbra. Flextronics- which will manufacture the iTbra- has listed their main business address on their contact page in Singapore.
The original patents that lead to the development of the iTbra were based on research done at Nanyang Technological University also based in Singapore.
Here is some more information concerning the trials in India. Cyrcadia has teamed up with Apollo Hospitals in India. They are a leading care provider in India and also specialize in medical tourism. They are a major player. This is from an overview put out by Cyrcadia Health from May 2015
CH (Cyrcadia Health) initial ASIA market launch through India’s Apollo Hospital will address largest breast cancer epidemic population in the world.A 10,000 patient screening trial is planned with Apollo in H2 2015
Here is a quote from Rob Royea from an interview with Wearable Technologies in March:
We have made excellent progress with Cyrcadia over the past year. We designed a highly scalable, wearable, conformable technology, and have a finalized clinical product released through Flextronics, the largest provider of medical wearable patches globally. Commercial prototypes are in progress as we now enter into our final clinical validation trial here in the US. El Camino Hospital, The Ohio State University and now Stanford’s Canary Center specializing in identifying early biomarkers are all joining in the trial which we expect will begin no later than May and be completed with the first phase of 173 patients by September 2015. Larger screening trials will be conducted at the National University Hospital in Singapore and Through Apollo Medical in India by the end of 2015. Product launch is projected for early 2016 in Asia and Europe with the US to follow later in 2016 post final FDA clearance.
Here is some information on Apollo Hospitals in India:
Apollo presence encompasses over 10,000 beds across 64 hospitals, more than 2200 pharmacies, over 100 primary care & diagnostic clinics, 115 telemedicine units across 9 countries, health insurance services, global projects consultancy, 15 academic institutions and a Research Foundation with a focus on global clinical trials, epidemiological studies, stem-cell and genetic research.